These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27291933)

  • 1. Safety data from randomized controlled trials: applying models for recurrent events.
    Hengelbrock J; Gillhaus J; Kloss S; Leverkus F
    Pharm Stat; 2016 Jul; 15(4):315-23. PubMed ID: 27291933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical issues in the analysis of adverse events in time-to-event data.
    Allignol A; Beyersmann J; Schmoor C
    Pharm Stat; 2016 Jul; 15(4):297-305. PubMed ID: 26929180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of varying the event generation process in simulation studies of statistical methods for recurrent events.
    Metcalfe C; Thompson SG
    Stat Med; 2006 Jan; 25(1):165-79. PubMed ID: 16217859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic comparison of recurrent event models for application to composite endpoints.
    Ozga AK; Kieser M; Rauch G
    BMC Med Res Methodol; 2018 Jan; 18(1):2. PubMed ID: 29301487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysing adverse events by time-to-event models: the CLEOPATRA study.
    Proctor T; Schumacher M
    Pharm Stat; 2016 Jul; 15(4):306-14. PubMed ID: 27313144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical methods to analyze adverse events data of randomized clinical trials.
    Siddiqui O
    J Biopharm Stat; 2009 Sep; 19(5):889-99. PubMed ID: 20183450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is intraoperative dexmedetomidine a new option for postoperative pain treatment? A meta-analysis of randomized controlled trials.
    Schnabel A; Meyer-Frießem CH; Reichl SU; Zahn PK; Pogatzki-Zahn EM
    Pain; 2013 Jul; 154(7):1140-9. PubMed ID: 23706726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of recurrent events: a systematic review of randomised controlled trials of interventions to prevent falls.
    Donaldson MG; Sobolev B; Cook WL; Janssen PA; Khan KM
    Age Ageing; 2009 Mar; 38(2):151-5. PubMed ID: 19106254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.
    Xu R; Mehrotra DV; Shaw PA
    Pharm Stat; 2019 May; 18(3):366-376. PubMed ID: 30706642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis for recurrent event data: an application to childhood infectious diseases.
    Kelly PJ; Lim LL
    Stat Med; 2000 Jan; 19(1):13-33. PubMed ID: 10623910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dealing with competing risks: testing covariates and calculating sample size.
    Pintilie M
    Stat Med; 2002 Nov; 21(22):3317-24. PubMed ID: 12407674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the treatment effect in a clinical trial when recurrent events define the endpoint.
    Mahé C; Chevret S
    Stat Med; 1999 Jul; 18(14):1821-9; discussion 1831. PubMed ID: 10407253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoglycemic events analysis via recurrent time-to-event (HEART) models.
    Fu H; Luo J; Qu Y
    J Biopharm Stat; 2016; 26(2):280-98. PubMed ID: 25437847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.
    Varadhan R; Weiss CO; Segal JB; Wu AW; Scharfstein D; Boyd C
    Med Care; 2010 Jun; 48(6 Suppl):S96-105. PubMed ID: 20473207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tests for multivariate recurrent events in the presence of a terminal event.
    Chen BE; Cook RJ
    Biostatistics; 2004 Jan; 5(1):129-43. PubMed ID: 14744832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model.
    Conlon AS; Taylor JM; Sargent DJ
    Biometrics; 2015 Jun; 71(2):460-8. PubMed ID: 25585942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.